A simpler solution with once- daily dosing and reduced risk of nocturnal hypoglycaemia
When treated with once-daily Ryzodeg®, people with type 2 diabetes achieved similar blood sugar control with half the number of daily injections, significantly lower total daily insulin dose and significantly reduced risk of nocturnal hypoglycaemia in the Step by Step trial compared with once-daily insulin glargine U100 plus once-daily insulin aspart after 26 weeks — says a press release.
Ryzodeg® is a combination of insulin degludec and insulin aspart (IDegAsp) in one pen for the treatment of people with type 2 diabetes. The results from the Step by Step trial were presented at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD 2018) in Berlin, Germany.
“These trial results show that once-daily IDegAsp can offer people with type 2 diabetes a much simpler option with fewer injections compared with insulin glargine U100 plus insulin aspart, to achieve effective blood sugar control,” said Dr Athena Philis-Tsimikas, Step by Step lead investigator and corporate vice president, Scripps Whittier Diabetes Institute.
“Hypoglycaemic episodes, especially at night, are often frightening for people with diabetes. Not only does once-daily Ryzodeg® offer a much simpler solution but it also significantly reduces the risk of nocturnal hypoglycaemia compared with basal-bolus treatment,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. “By reducing the number of daily injections, we hope that Ryzodeg® can help reduce the burden of diabetes, and make it easier for people with diabetes to comply with treatment and help them towards achieving better outcomes.”
